NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP
Year: 2015
Type: article
Abstract: Immunotherapy represents a promising area of therapy among neuro-oncology patients. However, early phase studies reveal unique challenges associated with assessment of radiological changes reflecting delayed responses or therapy-induced inflammation. Clinical benefit, including long-term survival and tumor regression, can still occur following initial apparent progression or appearance of new lesions. Refinement of response assessment criteria for neuro-oncology patients undergoing immunotherapy is therefore warranted. A multinational and multidisciplinary panel of neuro-oncology immunotherapy experts describes immunotherapy response assessment for neuro-oncology (iRANO) criteria that are based on guidance for determination of tumor progression outlined by the immune-related response criteria (irRC) and the response assessment in neuro-oncology (RANO) working group. Among patients who demonstrate imaging findings meeting RANO criteria for progressive disease (PD) within six months of initiating immunotherapy including the development of new lesions, confirmation of radiographic progression on follow-up imaging is recommended provided that the patient is not significantly worse clinically. The proposed criteria also include guidelines for use of corticosteroids. The role of advanced imaging techniques and measurement of clinical benefit endpoints including neurologic and immunologic functions are reviewed. The iRANO guidelines put forth herein will evolve successively to improve their utility as further experience from immunotherapy trials in neuro-oncology accumulate.
Source: Neuro-Oncology
Authors: Hideho Okada, Michael Weller, Raymond Huang, Gaetano Finocchiaro, Mark Gilbert, Wolfgang Wick, Benjamin Ellingson, Naoya Hashimoto, Ian Pollack, Alba Brandes, Enrico Franceschi, Christel Herold-Mende, Lakshmi Nayak, Ashok Panigrahy, Whitney Pope, Robert Prins, John Sampson, Patrick Wen, David Reardon
Institutions: University of California, San Francisco, University Hospital Zurich, Brigham and Women's Hospital, Fondazione IRCCS Istituto Neurologico Carlo Besta, National Institutes of Health, Heidelberg University, University Hospital Heidelberg, University of California, Los Angeles, The University of Osaka, University of Pittsburgh, Istituto delle Scienze Neurologiche di Bologna, Dana-Farber Cancer Institute, Duke University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2338775339